JP2024534189A5 - - Google Patents
Info
- Publication number
- JP2024534189A5 JP2024534189A5 JP2024513410A JP2024513410A JP2024534189A5 JP 2024534189 A5 JP2024534189 A5 JP 2024534189A5 JP 2024513410 A JP2024513410 A JP 2024513410A JP 2024513410 A JP2024513410 A JP 2024513410A JP 2024534189 A5 JP2024534189 A5 JP 2024534189A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- acid sequence
- nucleic acid
- recombinant hcmv
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239298P | 2021-08-31 | 2021-08-31 | |
| US63/239,298 | 2021-08-31 | ||
| US202263356386P | 2022-06-28 | 2022-06-28 | |
| US63/356,386 | 2022-06-28 | ||
| PCT/US2022/075670 WO2023034801A1 (en) | 2021-08-31 | 2022-08-30 | Recombinant hcmv vectors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534189A JP2024534189A (ja) | 2024-09-18 |
| JP2024534189A5 true JP2024534189A5 (https=) | 2025-09-08 |
Family
ID=83447741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513410A Pending JP2024534189A (ja) | 2021-08-31 | 2022-08-30 | 組換えｈｃｍｖベクター及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240384296A1 (https=) |
| EP (1) | EP4395809A1 (https=) |
| JP (1) | JP2024534189A (https=) |
| KR (1) | KR20240049807A (https=) |
| AU (1) | AU2022339765A1 (https=) |
| CA (1) | CA3226699A1 (https=) |
| CL (1) | CL2024000580A1 (https=) |
| CO (1) | CO2024001513A2 (https=) |
| IL (1) | IL310663A (https=) |
| MX (1) | MX2024001962A (https=) |
| TW (1) | TW202311531A (https=) |
| WO (1) | WO2023034801A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024059635A2 (en) * | 2022-09-13 | 2024-03-21 | Oregon Health And Science University | Universal t cell-based, cmv-vectored vaccine for influenza |
| CN120936375A (zh) * | 2023-04-14 | 2025-11-11 | 生物技术欧洲股份公司 | Hiv疫苗 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| TR201802741T4 (tr) | 2010-05-14 | 2018-03-21 | Univ Oregon Health & Science | Rekombinant hcmv ve rhcmv vektörleri ve bunların kullanımları. |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| DK2964769T3 (en) | 2013-03-05 | 2018-12-10 | Univ Oregon Health & Science | Cytomegalovirus vectors enabling control of T cell targeting |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| JP6816031B2 (ja) | 2015-02-10 | 2021-01-20 | オレゴン ヘルス アンド サイエンス ユニバーシティ | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| CN108474003A (zh) | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| CN109843321A (zh) | 2016-06-22 | 2019-06-04 | 国际艾滋病疫苗行动组织公司 | 作为结核病疫苗的重组巨细胞病毒载体 |
| US10532099B2 (en) | 2016-10-18 | 2020-01-14 | Oregon Health & Science University | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules |
| CN114402080B (zh) * | 2019-08-20 | 2024-09-13 | 俄勒冈健康与科学大学 | 人巨细胞病毒的ul18对t细胞应答的调节 |
-
2022
- 2022-08-30 JP JP2024513410A patent/JP2024534189A/ja active Pending
- 2022-08-30 US US18/687,050 patent/US20240384296A1/en active Pending
- 2022-08-30 WO PCT/US2022/075670 patent/WO2023034801A1/en not_active Ceased
- 2022-08-30 KR KR1020247006599A patent/KR20240049807A/ko active Pending
- 2022-08-30 EP EP22777537.6A patent/EP4395809A1/en active Pending
- 2022-08-30 MX MX2024001962A patent/MX2024001962A/es unknown
- 2022-08-30 IL IL310663A patent/IL310663A/en unknown
- 2022-08-30 CA CA3226699A patent/CA3226699A1/en active Pending
- 2022-08-30 AU AU2022339765A patent/AU2022339765A1/en active Pending
- 2022-08-30 TW TW111132771A patent/TW202311531A/zh unknown
-
2024
- 2024-02-13 CO CONC2024/0001513A patent/CO2024001513A2/es unknown
- 2024-02-26 CL CL2024000580A patent/CL2024000580A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11305015B2 (en) | Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules | |
| Cohen et al. | Modulating the immune response to genetic immunization | |
| JP6736109B2 (ja) | Ｐｄｌ１がブロッキングされた免疫逃避を抑制するためのｃａｒ−ｔ遺伝子組換えベクターおよびその構築方法と使用 | |
| US20200368333A1 (en) | Cmv vectors comprising microrna recognition elements | |
| JP6890831B2 (ja) | Ｈｉｖ予備免疫化および免疫療法 | |
| Lim et al. | Co-administration of avian influenza virus H5 plasmid DNA with chicken IL-15 and IL-18 enhanced chickens immune responses | |
| Tseng et al. | Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity | |
| JP2024534189A5 (https=) | ||
| JP2025118754A (ja) | Ｂ型肝炎ウイルス特異的なｔ細胞応答 | |
| JP2022544704A5 (https=) | ||
| CN102787119B (zh) | 治疗和/或预防病毒感染的产品及方法 | |
| JP2022544704A (ja) | ヒトサイトメガロウイルスのｕｌ１８によるｔ細胞応答の調節 | |
| JP6640717B2 (ja) | レトロウイルス複製ベクターと関連する免疫抑制成分 | |
| Qian et al. | Chimeric antigen receptor engineered cells and their clinical application in infectious disease | |
| CN120789239A (zh) | 重组溶瘤病毒和单克隆抗体联用在制备用于治疗hbv阳性肝癌的药物中的应用 | |
| WO2020214203A1 (en) | Replication deficient adenoviral vectors for hiv vaccine applications | |
| McKee et al. | 559. Generating Powerful Immune Responses Against Lentiviral Antigens: Using rSV40 Vector-Delivered Proinflammatory Cytokines to Potentiate Immune Responses vs. rSV40-Delivered Lentiviral Antigens | |
| HIV | 663. In Vitro Characterization of the Anti-Viral Activity of TT-034, a RNAi-Therapeutic Against the Hepatitis C Virus | |
| Liu et al. | 561. Recombinant Adenovirus Carrying Spike Gene Induces Effective Humoral and Cellular Immunity Against SARS-CoV in Rats | |
| Plaksin | Molecular and regulatory functions of MHC class I antigens in tumor metastasis | |
| Mukherjee et al. | Epstein-Barr Virus and its Capacity to Evade the Immune System to Cause Cancer | |
| HK1260171A1 (en) | Cmv vectors comprising microrna recognition elements |